Aridis Pharmaceuticals, Inc. signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pharmaceuticals for the prevention and treatment of infectious diseases with a focus on unmet needs in global health and biodefense. Aridis and MappBio have committed to work exclusively with each other to expeditiously complete definitive licensing agreements MappBio's pan-Ebola and pan-Marburg mAb programs are currently in Phase 1 clinical studies and both products have shown best-in-class protection against live virus challenges in non-human primates. The Strategic National Stockpile is a federally funded program that acquires, stores, and distributes medical countermeasures in the event of a public health emergency.